Insider Trading activities of Kite Pharma, Inc. insiders. , Part 2

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Kite Pharma, Inc. since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Kite Pharma, Inc. since year 2005. (See page 1 of this report.) Table 2 shows the detailed insider transactions of Kite Pharma, Inc. since 2005. The reporting company's ticker symbol is KITE. The reporting company's CIK number is 1510580.
The total value of stock buying since 2005 is $5,803,660.
The total value of stock sales since 2005 is $197,656,377.
The total value of stock option exercises since 2005 is $15,164,987.


 1   2 

Table 2. Detailed insider stock purchases, sales, and option exercises of Kite Pharma, Inc. insiders (KITE) , Part 2
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2016-01-15 Wiezorek Jeffrey (SVP Clinical Development) Sale 9,000 55.41 498,716
2016-01-15 Wiezorek Jeffrey (SVP Clinical Development) Option Ex 9,000 6.89 62,010
2016-01-15 Sproule Rizwana F (VP Regulatory Affairs) Sale 6,800 54.78 372,531
2016-01-15 Sproule Rizwana F (VP Regulatory Affairs) Option Ex 6,800 1.35 9,180
2016-01-15 Roberts Margo R (Chief Scientific Officer) Sale 6,145 55.34 340,082
2016-01-15 Roberts Margo R (Chief Scientific Officer) Option Ex 6,145 8.85 54,383
2016-01-04 Better Marc (VP, Product Sciences) Sale 9,000 61.73 555,570
2016-01-04 Better Marc (VP, Product Sciences) Option Ex 9,000 .38 3,420
2015-12-28 Butitta Cynthia M (COO and CFO) Sale 10,000 61.70 616,950
2015-12-28 Butitta Cynthia M (COO and CFO) Option Ex 10,000 1.35 13,500
2015-12-15 Wiezorek Jeffrey (SVP Clinical Development) Sale 9,000 64.02 576,180
2015-12-15 Wiezorek Jeffrey (SVP Clinical Development) Option Ex 9,000 6.89 62,010
2015-12-15 Sproule Rizwana F (VP Regulatory Affairs) Sale 9,567 64.11 613,369
2015-12-15 Sproule Rizwana F (VP Regulatory Affairs) Option Ex 9,567 1.35 12,915
2015-12-15 Roberts Margo R (Chief Scientific Officer) Sale 6,145 64.00 393,280
2015-12-15 Roberts Margo R (Chief Scientific Officer) Option Ex 6,145 8.85 54,383
2015-12-01 Better Marc (VP, Product Sciences) Sale 9,000 77.95 701,514
2015-12-01 Better Marc (VP, Product Sciences) Option Ex 9,000 .38 3,420
2015-11-27 Butitta Cynthia M (COO and CFO) Sale 15,000 86.62 1,299,375
2015-11-27 Butitta Cynthia M (COO and CFO) Option Ex 15,000 1.35 20,250
2015-11-16 Wiezorek Jeffrey (SVP Clinical Development) Sale 9,000 78.42 705,744
2015-11-16 Wiezorek Jeffrey (SVP Clinical Development) Option Ex 9,000 6.89 62,010
2015-11-16 Sproule Rizwana F (VP Regulatory Affairs) Sale 9,567 78.42 750,263
2015-11-16 Sproule Rizwana F (VP Regulatory Affairs) Option Ex 9,567 1.35 12,915
2015-11-16 Roberts Margo R (Chief Scientific Officer) Sale 6,145 78.26 480,907
2015-11-16 Roberts Margo R (Chief Scientific Officer) Option Ex 6,145 8.85 54,383
2015-11-10 Chang David D (EVP, R&D, Chief Medical Off.) Sale 30,800 80.02 2,464,616
2015-11-10 Chang David D (EVP, R&D, Chief Medical Off.) Option Ex 30,800 6.89 212,212
2015-11-10 Butitta Cynthia M (COO and CFO) Sale 5,000 80.00 400,000
2015-11-10 Butitta Cynthia M (COO and CFO) Option Ex 5,000 1.35 6,750
2015-11-02 Chang David D (EVP, R&D, Chief Medical Off.) Sale 7,700 70.11 539,870
2015-11-02 Chang David D (EVP, R&D, Chief Medical Off.) Option Ex 7,700 6.89 53,053
2015-11-02 Better Marc (VP, Product Sciences) Sale 9,000 70.59 635,310
2015-11-02 Better Marc (VP, Product Sciences) Option Ex 9,000 .38 3,420
2015-10-27 Butitta Cynthia M (COO and CFO) Sale 10,000 70.26 702,570
2015-10-27 Butitta Cynthia M (COO and CFO) Option Ex 10,000 1.35 13,500
2015-10-15 Wiezorek Jeffrey (SVP Clinical Development) Sale 9,000 62.45 562,068
2015-10-15 Wiezorek Jeffrey (SVP Clinical Development) Option Ex 9,000 6.89 62,010
2015-10-15 Sproule Rizwana F (VP Regulatory Affairs) Sale 9,567 62.34 596,425
2015-10-15 Sproule Rizwana F (VP Regulatory Affairs) Option Ex 9,567 1.35 12,915
2015-10-15 Roberts Margo R (Chief Scientific Officer) Sale 6,145 62.47 383,865
2015-10-15 Roberts Margo R (Chief Scientific Officer) Option Ex 6,145 8.85 54,383
2015-10-01 Chang David D (EVP, R&D, Chief Medical Off.) Sale 7,700 55.11 424,347
2015-10-01 Chang David D (EVP, R&D, Chief Medical Off.) Option Ex 7,700 6.89 53,053
2015-10-01 Better Marc (VP, Product Sciences) Sale 9,000 55.38 498,384
2015-10-01 Better Marc (VP, Product Sciences) Option Ex 9,000 .38 3,420
2015-09-28 Butitta Cynthia M (COO and CFO) Sale 10,000 55.78 557,800
2015-09-28 Butitta Cynthia M (COO and CFO) Option Ex 10,000 1.35 13,500
2015-09-15 Wiezorek Jeffrey (VP Clinical Development) Sale 9,000 64.34 579,060
2015-09-15 Wiezorek Jeffrey (VP Clinical Development) Option Ex 9,000 6.89 62,010
2015-09-15 Sproule Rizwana F (VP Regulatory Affairs) Sale 9,567 64.64 618,382
2015-09-15 Sproule Rizwana F (VP Regulatory Affairs) Option Ex 9,567 1.35 12,915
2015-09-15 Roberts Margo R (Chief Scientific Officer) Sale 6,145 64.32 395,246
2015-09-15 Roberts Margo R (Chief Scientific Officer) Option Ex 6,145 8.85 54,383
2015-09-08 Chang David D (EVP, R&D, Chief Medical Off.) Sale 7,384 55.00 406,120
2015-09-08 Chang David D (EVP, R&D, Chief Medical Off.) Option Ex 7,384 6.89 50,875
2015-09-03 Chang David D (EVP, R&D, Chief Medical Off.) Sale 316 55.00 17,380
2015-09-03 Chang David D (EVP, R&D, Chief Medical Off.) Option Ex 316 6.89 2,177
2015-09-01 Better Marc (VP, Product Sciences) Sale 9,000 52.20 469,800
2015-09-01 Better Marc (VP, Product Sciences) Option Ex 9,000 .38 3,420
2015-08-27 Butitta Cynthia M (COO and CFO) Sale 10,000 53.60 536,000
2015-08-27 Butitta Cynthia M (COO and CFO) Option Ex 10,000 1.35 13,500
2015-08-17 Wiezorek Jeffrey (VP Clinical Development) Sale 9,000 61.08 549,747
2015-08-17 Wiezorek Jeffrey (VP Clinical Development) Option Ex 9,000 6.89 62,010
2015-08-17 Sproule Rizwana F (VP Regulatory Affairs) Sale 9,567 60.98 583,366
2015-08-17 Sproule Rizwana F (VP Regulatory Affairs) Option Ex 9,567 1.35 12,915
2015-08-17 Roberts Margo R (Chief Scientific Officer) Sale 6,145 60.93 374,414
2015-08-17 Roberts Margo R (Chief Scientific Officer) Option Ex 6,145 8.85 54,383
2015-08-03 Chang David D (EVP, R&D, Chief Medical Off.) Sale 7,700 72.56 558,712
2015-08-03 Chang David D (EVP, R&D, Chief Medical Off.) Option Ex 7,700 6.89 53,053
2015-08-03 Better Marc (VP, Product Sciences) Sale 9,000 72.64 653,760
2015-08-03 Better Marc (VP, Product Sciences) Option Ex 9,000 .38 3,420
2015-07-27 Butitta Cynthia M (COO and CFO) Sale 10,000 68.55 685,450
2015-07-27 Butitta Cynthia M (COO and CFO) Option Ex 10,000 1.35 13,500
2015-07-15 Wiezorek Jeffrey (VP Clinical Development) Sale 9,000 71.73 645,588
2015-07-15 Wiezorek Jeffrey (VP Clinical Development) Option Ex 9,000 6.89 62,010
2015-07-15 Sproule Rizwana F (VP Regulatory Affairs) Sale 9,567 71.90 687,867
2015-07-15 Sproule Rizwana F (VP Regulatory Affairs) Option Ex 9,567 1.35 12,915
2015-07-15 Roberts Margo R (Chief Scientific Officer) Sale 22,167 71.66 1,588,442
2015-07-15 Roberts Margo R (Chief Scientific Officer) Option Ex 22,167 8.85 196,177
2015-07-01 Chang David D (EVP, R&D, Chief Medical Off.) Sale 7,700 62.14 478,501
2015-07-01 Chang David D (EVP, R&D, Chief Medical Off.) Option Ex 7,700 6.89 53,053
2015-07-01 Better Marc (VP, Product Sciences) Sale 9,000 61.97 557,757
2015-07-01 Better Marc (VP, Product Sciences) Option Ex 9,000 .38 3,420
2015-06-30 Champsi Farah (Director) Sale 664,102 62.55 41,538,251
2015-06-29 Butitta Cynthia M (COO and CFO) Sale 10,000 59.88 598,770
2015-06-29 Butitta Cynthia M (COO and CFO) Option Ex 10,000 1.35 13,500
2015-06-15 Chang David D (EVP, R&D, Chief Medical Off.) Sale 7,700 56.97 438,645
2015-06-15 Chang David D (EVP, R&D, Chief Medical Off.) Option Ex 7,700 6.89 53,053
2015-06-15 Wiezorek Jeffrey (VP Clinical Development) Sale 9,000 56.95 512,550
2015-06-15 Wiezorek Jeffrey (VP Clinical Development) Option Ex 9,000 6.89 62,010
2015-06-15 Sproule Rizwana F (VP Regulatory Affairs) Sale 9,567 56.93 544,678
2015-06-15 Sproule Rizwana F (VP Regulatory Affairs) Option Ex 9,567 1.35 12,915
2015-06-15 Roberts Margo R (Chief Scientific Officer) Sale 8,625 56.97 491,392
2015-06-15 Roberts Margo R (Chief Scientific Officer) Option Ex 8,625 .70 6,037
2015-06-02 Nussbaum Ran (Director) Sale 224,674 55.67 12,508,724
2015-06-01 Nussbaum Ran (Director) Sale 80,760 56.29 4,545,980
2015-06-01 Better Marc (VP, Product Sciences) Sale 9,000 55.48 499,292
2015-06-01 Better Marc (VP, Product Sciences) Option Ex 9,000 .38 3,420
2015-05-27 Butitta Cynthia M (COO and CFO) Sale 10,000 50.95 509,510
2015-05-27 Butitta Cynthia M (COO and CFO) Option Ex 10,000 1.35 13,500
2015-05-15 Wiezorek Jeffrey (VP Clinical Development) Sale 9,000 50.93 458,352
2015-05-15 Wiezorek Jeffrey (VP Clinical Development) Option Ex 9,000 6.89 62,010
2015-05-15 Sproule Rizwana F (VP Regulatory Affairs) Sale 9,567 50.95 487,438
2015-05-15 Sproule Rizwana F (VP Regulatory Affairs) Option Ex 9,567 1.35 12,915
2015-05-15 Roberts Margo R (Chief Scientific Officer) Sale 8,625 50.92 439,185
2015-05-15 Roberts Margo R (Chief Scientific Officer) Option Ex 8,625 .70 6,037
2015-05-01 Better Marc (VP, Product Sciences) Sale 9,000 51.02 459,207
2015-05-01 Better Marc (VP, Product Sciences) Option Ex 9,000 .38 3,420
2015-04-27 Butitta Cynthia M (COO and CFO) Sale 10,000 59.76 597,620
2015-03-30 Nussbaum Ran (Director) Sale 115,857 59.91 6,941,456
2015-03-27 Nussbaum Ran (Director) Sale 77,873 61.24 4,769,020
2014-06-25 Chang David D (EVP, R&D, Chief Medical Off.) Buy 4,000 17.00 68,000
2014-06-25 Wiezorek Jeffrey (VP Clinical Development) Buy 4,000 17.00 68,000
 1   2 

Insider trading activities including stock purchases, stock sales, and option exercises of KITE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Kite Pharma, Inc. (symbol KITE, CIK number 1510580) see the Securities and Exchange Commission (SEC) website.